How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies.
asbestos
cancer
chemotherapy
immunothearpy
mesothelioma
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
01
2022
accepted:
24
02
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
epublish
Résumé
Asbestos-induced preclinical mouse models of mesothelioma produce tumors that are very similar to those that develop in humans and thus represent an ideal platform to study this rare, universally fatal tumor type. Our team and a number of other research groups have established such models as a stepping stone to new treatments, including chemotherapy, immunotherapy and other approaches that have been/are being translated into clinical trials. In some cases this work has led to changes in mesothelioma treatment practice and over the last 30 years these models and studies have led to trials which have improved the response rate in mesothelioma from less than 10% to over 50%. Mouse models have had a vital role in that improvement and will continue to play a key role in the future success of mesothelioma immunotherapy. In this review we focus only on these original inbred mouse models, the large number of preclinical studies conducted using them and their contribution to current and future clinical therapy for mesothelioma.
Identifiants
pubmed: 35431929
doi: 10.3389/fphar.2022.858557
pii: 858557
pmc: PMC9008447
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
858557Informations de copyright
Copyright © 2022 Robinson, Redwood and Creaney.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncoimmunology. 2018 Jul 30;7(10):e1494111
pubmed: 30288361
J Immunol. 1999 May 15;162(10):5838-45
pubmed: 10229818
J Immunol. 2003 Nov 15;171(10):5051-63
pubmed: 14607902
Oncoimmunology. 2015 Feb 25;4(5):e1005501
pubmed: 26155402
J Immunol. 2004 Nov 15;173(10):5923-8
pubmed: 15528325
BMC Cancer. 2017 Oct 16;17(1):684
pubmed: 29037232
Clin Dev Immunol. 2010;2010:539519
pubmed: 20976125
J Immunol. 2009 May 1;182(9):5217-24
pubmed: 19380767
Expert Opin Pharmacother. 2004 Dec;5(12):2441-9
pubmed: 15571462
Nat Rev Immunol. 2010 Jun;10(6):403-14
pubmed: 20498667
Cancer Res. 2005 Sep 1;65(17):7580-4
pubmed: 16140921
Immunol Cell Biol. 1999 Dec;77(6):552-8
pubmed: 10571677
Cancer Gene Ther. 2001 Aug;8(8):580-8
pubmed: 11571536
Int Immunol. 2008 Nov;20(11):1467-79
pubmed: 18824504
Chest. 2017 Apr;151(4):891-897
pubmed: 27769776
Adv Drug Deliv Rev. 2006 Oct 1;58(8):975-90
pubmed: 17005292
Sci Rep. 2015 Jul 21;5:12298
pubmed: 26193793
Lancet Oncol. 2020 Sep;21(9):1213-1223
pubmed: 32888453
Cancer Treat Rev. 1995 May;21(3):273-88
pubmed: 7656268
Expert Opin Biol Ther. 2005 Aug;5(8):1039-49
pubmed: 16050782
Discov Med. 2005 Jun;5(27):265-70
pubmed: 20704886
Am J Respir Cell Mol Biol. 1998 Nov;19(5):738-46
pubmed: 9806738
Sci Rep. 2019 Oct 10;9(1):14640
pubmed: 31601975
Cancer Res. 2003 Aug 1;63(15):4490-6
pubmed: 12907622
J Immunol Res. 2014;2014:789069
pubmed: 24955376
Int Immunol. 2012 Jun;24(6):357-68
pubmed: 22354912
Br J Cancer. 1969 Sep;23(3):567-81
pubmed: 5360333
J Clin Oncol. 1999 Jan;17(1):25-30
pubmed: 10458214
Oncoimmunology. 2015 May 11;4(7):e1011492
pubmed: 26140232
Cancer Immunol Immunother. 2009 Aug;58(8):1219-28
pubmed: 19052741
Int J Cancer. 1992 Dec 2;52(6):881-6
pubmed: 1459729
J Immunol. 2008 Feb 1;180(3):1535-44
pubmed: 18209049
Aust N Z J Med. 1989 Jun;19(3):281-91
pubmed: 2775050
Int Rev Immunol. 2012 Aug;31(4):246-66
pubmed: 22804570
Lung Cancer. 2001 May;32(2):197-201
pubmed: 11325491
Semin Oncol. 2002 Feb;29(1):82-96
pubmed: 11836673
J Immunother. 1998 Sep;21(5):389-98
pubmed: 9789201
J Interferon Cytokine Res. 1995 Mar;15(3):213-23
pubmed: 7584666
J Immunother. 2013 Sep;36(7):365-72
pubmed: 23924788
Cancer Gene Ther. 1996 Sep-Oct;3(5):321-30
pubmed: 8894251
Nat Rev Cancer. 2005 May;5(5):397-405
pubmed: 15864281
J Immunother. 1998 May;21(3):211-7
pubmed: 9610913
Cancer Gene Ther. 2000 May;7(5):663-70
pubmed: 10830713
Aust N Z J Med. 1993 Dec;23(6):683-7
pubmed: 8141698
Oncoimmunology. 2019 Nov 7;9(1):1684714
pubmed: 32002299
Immunol Cell Biol. 1997 Aug;75(4):356-9
pubmed: 9315477
Growth Factors. 1994;11(1):29-44
pubmed: 7833058
Eur J Immunol. 2015 Jan;45(1):49-59
pubmed: 25316312
Cancer Res. 1997 Aug 1;57(15):3200-7
pubmed: 9242450
Br J Cancer. 2002 Aug 27;87(5):491-6
pubmed: 12189542
Clin Exp Allergy. 1995 Jul;25(7):634-42
pubmed: 8521182
Cancer Res. 2006 Jan 15;66(2):601-4
pubmed: 16423984
Cancer Immunol Immunother. 1994 Dec;39(6):347-59
pubmed: 8001022
PLoS One. 2014 Sep 22;9(9):e107894
pubmed: 25243472
BMC Cancer. 2017 Jun 2;17(1):396
pubmed: 28577549
Cancer Res. 1999 Mar 1;59(5):1071-9
pubmed: 10070965
Int J Cancer. 1994 Oct 15;59(2):212-6
pubmed: 7927922
Cancer Gene Ther. 2006 Oct;13(10):897-904
pubmed: 16439992
J Immunol. 2000 Dec 1;165(11):6047-55
pubmed: 11086036
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1395-9
pubmed: 21642245
J Transl Med. 2014 Sep 04;12:245
pubmed: 25186961
Cancer Chemother Pharmacol. 1991;28(5):319-30
pubmed: 1914074
J Immunol. 2003 May 15;170(10):4905-13
pubmed: 12734333
Cancer Res. 2002 Apr 15;62(8):2353-8
pubmed: 11956096
J Immunol Methods. 1994 May 2;171(1):131-7
pubmed: 8176234
Expert Rev Respir Med. 2019 Feb;13(2):181-192
pubmed: 30596292
Ann Oncol. 2015 Dec;26(12):2483-90
pubmed: 26386124
BMC Cancer. 2014 Dec 17;14:969
pubmed: 25518732
J Interferon Res. 1993 Feb;13(1):9-12
pubmed: 8454913